-
Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy
Tuesday, June 14, 2022 - 5:33am | 544Read More...Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration. Eli Lilly & Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that the FDA approved Olumiant, a once-daily pill, as the...
-
Eli Lilly/Incyte's Baricitinib Shows Benefit In Patchy Hair Loss Disorder
Wednesday, March 3, 2021 - 10:43am | 297Read More...Eli Lilly and Co (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announces top-line results from Phase 3 BRAVE-AA2 study evaluating baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA). AA is an autoimmune disorder that usually results in...
